GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » Cyclically Adjusted Price-to-FCF

Xenetic Biosciences (Xenetic Biosciences) Cyclically Adjusted Price-to-FCF : (As of May. 19, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Xenetic Biosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Xenetic Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences Cyclically Adjusted Price-to-FCF Chart

Xenetic Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xenetic Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xenetic Biosciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Xenetic Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Xenetic Biosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Xenetic Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Xenetic Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.752/131.7762*131.7762
=-0.752

Current CPI (Mar. 2024) = 131.7762.

Xenetic Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -95.147 100.560 -124.683
201409 -79.088 100.428 -103.775
201412 -76.457 99.070 -101.698
201503 -58.171 99.621 -76.947
201506 -5.543 100.684 -7.255
201509 -55.857 100.392 -73.319
201512 -31.886 99.792 -42.106
201603 -47.105 100.470 -61.783
201606 -20.908 101.688 -27.094
201609 -13.720 101.861 -17.749
201612 -67.014 101.863 -86.694
201703 3.887 102.862 4.980
201706 -27.288 103.349 -34.794
201709 -22.425 104.136 -28.377
201712 66.274 104.011 83.965
201803 -22.836 105.290 -28.581
201806 -28.603 106.317 -35.452
201809 -21.385 106.507 -26.459
201812 -13.346 105.998 -16.592
201903 -15.494 107.251 -19.037
201906 -11.943 108.070 -14.563
201909 -6.259 108.329 -7.614
201912 -2.764 108.420 -3.359
202003 -1.607 108.902 -1.945
202006 -2.068 108.767 -2.505
202009 -1.606 109.815 -1.927
202012 -1.413 109.897 -1.694
202103 -1.736 111.754 -2.047
202106 -0.831 114.631 -0.955
202109 -1.017 115.734 -1.158
202112 -1.085 117.630 -1.215
202203 -1.554 121.301 -1.688
202206 -0.518 125.017 -0.546
202209 -0.753 125.227 -0.792
202212 -0.499 125.222 -0.525
202303 -0.726 127.348 -0.751
202306 -0.832 128.729 -0.852
202309 -0.620 129.860 -0.629
202312 -0.515 129.419 -0.524
202403 -0.752 131.776 -0.752

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xenetic Biosciences  (NAS:XBIO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Xenetic Biosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences (Xenetic Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110

Xenetic Biosciences (Xenetic Biosciences) Headlines